{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:23:19Z","timestamp":1789705399913,"version":"4.0.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32GM086330"],"award-info":[{"award-number":["T32GM086330"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11864-025-01378-6","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T10:02:56Z","timestamp":1773741776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Menin Inhibitors: A New Era of Targeted Therapies in Acute Myeloid Leukemia"],"prefix":"10.1007","volume":"27","author":[{"given":"Daniel T.","family":"Peters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jess","family":"Hatfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mollie","family":"Reese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua F.","family":"Zeidner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"1378_CR1","unstructured":"NIH: Cancer Stat Facts. Leukemia \u2014 Acute myeloid leukemia (AML), cancer statistics: reports on cancer. National cancer institute: Surveillance, Epidemiology, and end results program. NIH; 2025."},{"key":"1378_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"1378_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/bjh.16857","volume":"191","author":"A Bataller","year":"2020","unstructured":"Bataller A, O\u00f1ate G, Diaz-Bey\u00e1 M, et al. Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease. Br J Haematol. 2020;191:52\u201361.","journal-title":"Br J Haematol"},{"key":"1378_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/PPO.0000000000000571","volume":"28","author":"M Swaminathan","year":"2022","unstructured":"Swaminathan M, Bourgeois W, Armstrong SA, et al. Menin inhibitors in acute myeloid leukemia\u2014what does the future hold? Cancer J. 2022;28:62\u20136.","journal-title":"Cancer J"},{"key":"1378_CR5","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1038\/s41375-024-02333-4","volume":"38","author":"A Hern\u00e1ndez-S\u00e1nchez","year":"2024","unstructured":"Hern\u00e1ndez-S\u00e1nchez A, Gonz\u00e1lez T, Sobas M, et al. Rearrangements involving 11q23.3\/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study. Leukemia. 2024;38:1929\u201337.","journal-title":"Leukemia"},{"key":"1378_CR6","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1002\/cncr.34728","volume":"129","author":"D Nguyen","year":"2023","unstructured":"Nguyen D, Kantarjian HM, Short NJ, et al. Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation. Cancer. 2023;129:1856\u201365.","journal-title":"Cancer"},{"key":"1378_CR7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41408-021-00557-6","volume":"11","author":"GC Issa","year":"2021","unstructured":"Issa GC, Zarka J, Sasaki K, et al. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J. 2021;11:162.","journal-title":"Blood Cancer J"},{"key":"1378_CR8","doi-asserted-by":"publisher","first-page":"15519","DOI":"10.1021\/acs.jmedchem.1c00872","volume":"64","author":"H Lei","year":"2021","unstructured":"Lei H, Zhang SQ, Fan S, et al. Recent progress of small molecule Menin-MLL interaction inhibitors as therapeutic agents for acute leukemia. J Med Chem. 2021;64:15519\u201333.","journal-title":"J Med Chem"},{"key":"1378_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16223743","author":"S Dhiman","year":"2024","unstructured":"Dhiman S, Dhillon V, Balasubramanian SK. Targeting menin in acute myeloid leukemia: therapeutic advances and future directions. Cancers (Basel). 2024;16(22):Article 3743. https:\/\/doi.org\/10.3390\/cancers16223743.","journal-title":"Cancers (Basel)"},{"key":"1378_CR10","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/s41375-021-01309-y","volume":"35","author":"GC Issa","year":"2021","unstructured":"Issa GC, Ravandi F, DiNardo CD, et al. Therapeutic implications of menin inhibition in acute leukemias. Leukemia. 2021;35:2482\u201395.","journal-title":"Leukemia"},{"key":"1378_CR11","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s11899-020-00592-3","volume":"15","author":"SS Patel","year":"2020","unstructured":"Patel SS, Kluk MJ, Weinberg OK. NPM1 biology in myeloid neoplasia. Curr Hematol Malig Rep. 2020;15:350\u20139.","journal-title":"Curr Hematol Malig Rep"},{"key":"1378_CR12","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nchembio.773","volume":"8","author":"J Grembecka","year":"2012","unstructured":"Grembecka J, He S, Shi A, et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol. 2012;8:277\u201384.","journal-title":"Nat Chem Biol"},{"key":"1378_CR13","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1158\/2159-8290.CD-16-0237","volume":"6","author":"MW K\u00fchn","year":"2016","unstructured":"K\u00fchn MW, Song E, Feng Z, et al. Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia. Cancer Discov. 2016;6:1166\u201381.","journal-title":"Cancer Discov"},{"key":"1378_CR14","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1126\/science.aax5863","volume":"367","author":"HJ Uckelmann","year":"2020","unstructured":"Uckelmann HJ, Kim SM, Wong EM, et al. Therapeutic targeting of preleukemia cells in a mouse model of <\u2009i\u2009>\u2009NPM1\u2009mutant acute myeloid leukemia. Science. 2020;367:586\u201390.","journal-title":"Science"},{"key":"1378_CR15","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","volume":"36","author":"AV Krivtsov","year":"2019","unstructured":"Krivtsov AV, Evans K, Gadrey JY, et al. A Menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of <\u2009em\u2009>\u2009MLL-Rearranged leukemia. Cancer Cell. 2019;36:660\u2013e67311.","journal-title":"Cancer Cell"},{"key":"1378_CR16","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1172\/JCI129126","volume":"130","author":"S Klossowski","year":"2020","unstructured":"Klossowski S, Miao H, Kempinska K, et al. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. J Clin Invest. 2020;130:981\u201397.","journal-title":"J Clin Invest"},{"key":"1378_CR17","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1182\/blood.2023022480","volume":"144","author":"MC Kwon","year":"2024","unstructured":"Kwon MC, Thuring JW, Querolle O, et al. Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias. Blood. 2024;144:1206\u201320.","journal-title":"Blood"},{"key":"1378_CR18","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1182\/blood-2021-152050","volume":"138","author":"K Eguchi","year":"2021","unstructured":"Eguchi K, Shimizu T, Kato D, et al. Preclinical evaluation of a novel orally bioavailable menin-MLL interaction inhibitor, DSP-5336, for the treatment of acute leukemia patients with MLL-rearrangement or NPM1 mutation. Blood. 2021;138:3339\u20133339.","journal-title":"Blood"},{"key":"1378_CR19","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa GC, Aldoss I, DiPersio J, et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615:920\u20134.","journal-title":"Nature"},{"key":"1378_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/JCO.24.00826","volume":"43","author":"GC Issa","year":"2025","unstructured":"Issa GC, Aldoss I, Thirman MJ, et al. Menin Inhibition with revumenib for <\u2009i\u2009>\u2009KMT2A-Rearranged relapsed or refractory acute leukemia (AUGMENT-101). J Clin Oncol. 2025;43:75\u201384.","journal-title":"J Clin Oncol"},{"key":"1378_CR21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-194384","volume":"144","author":"I Aldoss","year":"2024","unstructured":"Aldoss I, Issa GC, Blachly JS, et al. Updated results and longer follow-up from the AUGMENT-101 phase 2 study of revumenib in all patients with relapsed or refractory (R\/R) KMT2Ar acute leukemia. Blood. 2024;144:211.","journal-title":"Blood"},{"key":"1378_CR22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025028357","author":"ML Arellano","year":"2025","unstructured":"Arellano ML, Thirman MJ, DiPersio JF, et al. Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. Blood. 2025;146(9):1065\u20131077. https:\/\/doi.org\/10.1182\/blood.2025028357.","journal-title":"Blood"},{"key":"1378_CR23","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","volume":"25","author":"ES Wang","year":"2024","unstructured":"Wang ES, Issa GC, Erba HP, et al. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial. Lancet Oncol. 2024;25:1310\u201324.","journal-title":"Lancet Oncol"},{"key":"1378_CR24","doi-asserted-by":"crossref","unstructured":"Wang ES, Montesinos P, Issa GC, et al. Ziftomenib in relapsed\/refractory (R\/R) NPM1-mutant acute myeloid leukemia (AML): phase 1b\/2 clinical activity and safety results from the pivotal KOMET-001 study. Am Soc Clin Oncol. 2025.","DOI":"10.1200\/JCO.2025.43.16_suppl.6506"},{"issue":"31","key":"1378_CR25","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1200\/JCO-25-01694","volume":"43","author":"ES Wang","year":"2025","unstructured":"Wang ES, Montesinos P, Foran J, et al. Ziftomenib in Relapsed or Refractory NPM1-Mutated AML. J Clin Oncol. 2025;43(31):3381\u201390.","journal-title":"J Clin Oncol"},{"key":"1378_CR26","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1182\/blood-2024-207106","volume":"144","author":"E Searle","year":"2024","unstructured":"Searle E, Recher C, Abdul-Hay M, et al. Bleximenib dose optimization and determination of RP2D from a phase 1 study in relapsed\/refractory acute leukemia patients with KMT2A and NPM1 alterations. Blood. 2024;144:212\u2013212.","journal-title":"Blood"},{"key":"1378_CR27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-172422","volume":"142","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Searle E, Abdul-Hay M, et al. A first-in-human phase 1 study of the menin-KMT2A (MLL1) inhibitor JNJ-75276617 in adult patients with relapsed\/refractory acute leukemia harboring KMT2A or NPM1 alterations. Blood. 2023;142:57.","journal-title":"Blood"},{"key":"1378_CR28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1182\/blood-2024-194827","volume":"144","author":"JF Zeidner","year":"2024","unstructured":"Zeidner JF, Yuda J, Watts JM, et al. Phase 1 results: first-in-human phase 1\/2 study of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia. Blood. 2024;144:213\u2013213.","journal-title":"Blood"},{"key":"1378_CR29","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1182\/blood-2025-763","volume":"146","author":"N Daver","year":"2025","unstructured":"Daver N, Zeidner J, Watts J, et al. Monotherapy update from phase 1 portion in Phase1\/2 trial of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia. Blood. 2025;146:763\u2013763.","journal-title":"Blood"},{"key":"1378_CR30","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1182\/blood-2025-765","volume":"146","author":"J Watts","year":"2025","unstructured":"Watts J, Borate U, Levis M, et al. Preliminary data from the ongoing phase 1 study of the menin-MLL inhibitor enzomenib (DSP-5336) in combination with venetoclax and azacitidine in patients with relapsed or refractory acute myeloid leukemia. Blood. 2025;146:765\u2013765.","journal-title":"Blood"},{"key":"1378_CR31","doi-asserted-by":"publisher","first-page":"TPS7064","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7064","volume":"40","author":"F Ravandi","year":"2022","unstructured":"Ravandi F, Kishtagari A, Carraway HE, et al. COVALENT-101: a phase 1 study of BMF-219, a novel oral irreversible menin inhibitor, in patients with relapsed\/refractory (R\/R) acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM). J Clin Oncol. 2022;40:TPS7064\u2013TPS7064.","journal-title":"J Clin Oncol"},{"key":"1378_CR32","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1182\/blood-2023-173149","volume":"142","author":"J Lancet","year":"2023","unstructured":"Lancet J, Ravandi F, Montesinos P, et al. Covalent menin inhibitor Bmf-219 in patients with relapsed or refractory (R\/R) acute leukemia (AL): preliminary phase 1 data from the Covalent-101 study. Blood. 2023;142:2916\u20132916.","journal-title":"Blood"},{"key":"1378_CR33","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1182\/blood-2024-198959","volume":"144","author":"D Wu","year":"2024","unstructured":"Wu D, Wang Y, Chen S, et al. A first-in-human phase 1\/2 study of the menin-KMT2A(MLL1) inhibitor BN104 in adult patients with relapsed or refractory acute leukemia. Blood. 2024;144:2879\u20132879.","journal-title":"Blood"},{"key":"1378_CR34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-204375","volume":"144","author":"GC Issa","year":"2024","unstructured":"Issa GC, Cuglievan B, Daver N, et al. Phase I\/II study of the all-oral combination of revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax (SAVE) in R\/R AML. Blood. 2024;144:216.","journal-title":"Blood"},{"key":"1378_CR35","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1182\/blood-2025-764","volume":"146","author":"G Issa","year":"2025","unstructured":"Issa G, Fathi A, Zeidan A, et al. Ziftomenib in combination with venetoclax and azacitidine in relapsed\/refractory NPM1-m or KMT2A-r acute myeloid leukemia: updated phase 1a\/b safety and clinical activity results from KOMET-007. Blood. 2025;146:764\u2013764.","journal-title":"Blood"},{"key":"1378_CR36","unstructured":"Wei AH, Esteve Reyner J, Garciaz S et al. RP2D determination of bleximenib in combination with VEN\u2009+\u2009AZA: Phase 1b study in ND & R\/R AML with KMT2A\/NPM1 alterations. Presented at the 30th European Hematology Association Annual Congress, Milan, Italy, 2025\/06\/12. 2025."},{"key":"1378_CR37","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1182\/blood-2025-3425","volume":"146","author":"I Aldoss","year":"2025","unstructured":"Aldoss I, Shultz C, Hunter B, et al. Phase 1 study of revumenib in combination with intensive chemotherapy (IC) in patients (Pts) with newly diagnosed (ND) acute myeloid leukemia (AML) harboring genetic alterations in KMT2A, NPM1, or NUP98: SNDX-5613-0708. Blood. 2025;146:3425\u20133425.","journal-title":"Blood"},{"key":"1378_CR38","doi-asserted-by":"publisher","first-page":"5206","DOI":"10.1182\/blood-2025-5206","volume":"146","author":"A Mims","year":"2025","unstructured":"Mims A, Wei L, McLaughlin E, et al. Revumenib in combination with intensive induction and consolidation for newly diagnosed patients with NPM1-mutated or KMT2A-rearranged acute myeloid leukemia: preliminary results from the phase 1b etctn 10596 study. Blood. 2025;146:5206\u20135206.","journal-title":"Blood"},{"key":"1378_CR39","unstructured":"Syndax, NCT06226571. : A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias, in clinicaltrials.gov, editor, 2025."},{"key":"1378_CR40","unstructured":"Erba H, Wang E, Fathi A et al. Ziftomenib combined with intensive induction chemotherapy (7\u2009+\u20093) in newly diagnosed NPM1-m or KMT2A-r acute myeloid leukemia (AML): updated phase 1a\/b results from KOMET-007. HemaSphere. 2025;9(S1):Abstract S136."},{"key":"1378_CR41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-207072","volume":"144","author":"C Recher","year":"2024","unstructured":"Recher C, O\u2019Nions J, Aldoss I, et al. Phase 1b study of Menin-KMT2A inhibitor Bleximenib in combination with intensive chemotherapy in newly diagnosed acute myeloid leukemia with KMT2Ar or NPM1 alterations. Blood. 2024;144:215.","journal-title":"Blood"},{"key":"1378_CR42","doi-asserted-by":"publisher","first-page":"5199","DOI":"10.1182\/blood-2025-5199","volume":"146","author":"H D\u00f6hner","year":"2025","unstructured":"D\u00f6hner H, Schuh A, Recher C, et al. Bleximenib in combination with intensive chemotherapy: a phase 1b study in newly diagnosed acute myeloid leukemia with KMT2A or NPM1 alterations. Blood. 2025;146:5199\u20135199.","journal-title":"Blood"},{"issue":"23","key":"1378_CR43","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1200\/JCO.25.00914","volume":"43","author":"JF Zeidner","year":"2025","unstructured":"Zeidner JF, Lin TL, Welkie RL, et al. Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML. J Clin Oncol. 2025;43(23):2606\u201315. https:\/\/doi.org\/10.1200\/JCO.25.00914.","journal-title":"J Clin Oncol."},{"key":"1378_CR44","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1182\/blood-2025-47","volume":"146","author":"W-Y Jen","year":"2025","unstructured":"Jen W-Y, DiNardo C, Short N, et al. Phase II study of the all-oral combination of revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML. Blood. 2025;146:47\u201347.","journal-title":"Blood"},{"key":"1378_CR45","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1182\/blood-2025-766","volume":"146","author":"G Roboz","year":"2025","unstructured":"Roboz G, Wang E, Fathi A, et al. Ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-m acute myeloid leukemia: phase 1b results from KOMET-007. Blood. 2025;146:766\u2013766.","journal-title":"Blood"},{"key":"1378_CR46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-198218","volume":"144","author":"AM Zeidan","year":"2024","unstructured":"Zeidan AM, Wang ES, Issa GC, et al. Ziftomenib combined with intensive induction (7\u2009+\u20093) in newly diagnosed NPM1-m or KMT2A-r acute myeloid leukemia: interim phase 1a results from KOMET-007. Blood. 2024;144:214.","journal-title":"Blood"},{"key":"1378_CR47","unstructured":"Stone R. NCT06313437: Revumenib in Combination With 7\u2009+\u20093\u2009+\u2009Midostaurin in AML, in clinicaltrials.gov, editor, 2025."},{"key":"1378_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107777","volume":"300","author":"J Ray","year":"2024","unstructured":"Ray J, Clegg B, Grembecka J, et al. Drug-resistant menin variants retain high binding affinity and interactions with MLL1. J Biol Chem. 2024;300:107777.","journal-title":"J Biol Chem"},{"key":"1378_CR49","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","volume":"615","author":"F Perner","year":"2023","unstructured":"Perner F, Stein EM, Wenge DV, et al. MEN1 mutations mediate clinical resistance to menin inhibition. Nature. 2023;615:913\u20139.","journal-title":"Nature"},{"key":"1378_CR50","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1182\/blood-2024-208887","volume":"144","author":"W Bourgeois","year":"2024","unstructured":"Bourgeois W, Cutler J, Rice HE, et al. Discerning the landscape of menin inhibitor resistance. Blood. 2024;144:724\u2013724.","journal-title":"Blood"},{"key":"1378_CR51","doi-asserted-by":"publisher","first-page":"5995","DOI":"10.1182\/blood-2024-203466","volume":"144","author":"GC Issa","year":"2024","unstructured":"Issa GC, Chin K-K, Blachly JS, et al. A phase II study of the menin inhibitor revumenib in leukemia associated with upregulation of HOX genes: trial in progress. Blood. 2024;144:5995\u20135995.","journal-title":"Blood"},{"key":"1378_CR52","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1038\/leu.2015.6","volume":"29","author":"DH Spencer","year":"2015","unstructured":"Spencer DH, Young MA, Lamprecht TL, et al. Epigenomic analysis of the HOX gene loci reveals mechanisms that may control canonical expression patterns in AML and normal hematopoietic cells. Leukemia. 2015;29:1279\u201389.","journal-title":"Leukemia"},{"key":"1378_CR53","volume-title":"Enrolled in phase 2 trial targeting residual disease in AML","author":"Break Through Cancer Announces First Patient","year":"2024","unstructured":"Break Through Cancer Announces First Patient. Enrolled in phase 2 trial targeting residual disease in AML. Cambridge, MA: Break Through Cancer; 2024."},{"key":"1378_CR54","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1182\/blood-2024-202895","volume":"144","author":"S Loo","year":"2024","unstructured":"Loo S, Iland H, Tiong IS, et al. Revumenib as pre-emptive therapy for measurable residual disease in NPM1 mutated or KMT2A-rearranged acute myeloid leukemia: a domain of the multi-arm ALLG AMLM26 intercept platform trial. Blood. 2024;144:223\u2013223.","journal-title":"Blood"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01378-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01378-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01378-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T22:04:26Z","timestamp":1773785066000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01378-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1378"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01378-6","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"30 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"D.T.P. has received honoraria for advisory boards from Syndax.J.F.Z. has served as a consultant for AbbVie, Astellas, AstraZeneca, Crossbow Therapeutics, Daiichi Sankyo, Foghorn, Genmab, Ipsen, Jazz, Johnson & Johnson, Kura Oncology, Neogenomics, Novartis, Relmada Therapeutics, Rigel, Sellas Life Sciences, Servier, Shattuck Labs, Sumitomo Pharma, and Syndax; and has received grant support outside of this work from AbbVie, Akesobio Pharma, Aptevo Therapeutics, Arog, Ascentage, AstraZeneca, Auron Therapeutics, Daiichi Sankyo, Faron, Jazz, Lin Biosciences, Loxo, Merck, Newave, Novartis, Sellas Life Sciences, Shattuck Labs, Stemline, Sumitomo Pharma, and Zentalis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"15"}}